Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) PT at $3.75

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have received an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $3.75.

Several research firms recently commented on HOWL. Wall Street Zen upgraded shares of Werewolf Therapeutics to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings cut Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.41 on Tuesday. The company has a market cap of $19.71 million, a price-to-earnings ratio of -0.53 and a beta of 0.29. Werewolf Therapeutics has a 1-year low of $0.27 and a 1-year high of $2.38. The stock’s fifty day moving average price is $0.38 and its 200 day moving average price is $0.59.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.00 million. As a group, equities research analysts anticipate that Werewolf Therapeutics will post -1.08 earnings per share for the current year.

Insider Activity

In other news, Director Luke Evnin sold 107,429 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the transaction, the insider owned 303,719 shares of the company’s stock, valued at $106,301.65. The trade was a 57.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,428,231 shares of company stock worth $942,811 over the last quarter. 23.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Bank of America Corp DE acquired a new position in shares of Werewolf Therapeutics during the second quarter worth $112,000. Renaissance Technologies LLC boosted its position in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new position in Werewolf Therapeutics in the third quarter valued at approximately $304,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.